Hemab Therapeutics shows unusually heavy, broad-based insider buying and an attractive valuation against its analyst target, but a thin risk-reward gap that fails the engine's own gate, quality below the investability floor, and a purely speculative small-cap classification keep conviction and position sizing at essentially zero.
Thesis pillars
- Heavy Broad Based Insider Buying→Stable
- Attractive Valuation Vs Analyst Target↑Improving
- Failed Asymmetry Gate→Stable
- +2 more pillars — see the Why tab for full reasoning
Hemab Therapeutics Holdings, In (COAG) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $46.66: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality.
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is... Read more
Sell if holding. Engine safety override at $46.66: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.3/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
Recent developments
updated 2026-07-25Recent Developments — Hemab Therapeutics Holdings, In
Latest news
- NEWS Hemab Therapeutics Presents Clinical, Preclinical Data From Sutacimig In Glanzmann Thrombasthenia And Factor VII Deficie — benzinga Jul 14, 2026 positive
- NEWS Jefferies Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $47 — benzinga Jul 13, 2026 positive
- NEWS Hemab Advances Bleeding Disorder Pipeline — benzinga Jul 13, 2026 positive
- NEWS CORRECTION: Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target To $55 — benzinga Jul 13, 2026 positive
- NEWS Wedbush Reiterates Outperform on Hemab Therapeutics Hldgs, Maintains $55 Price Target — benzinga Jul 13, 2026 positive
Generated 2026-07-25T11:07:03Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $46.66: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $44.00. Score 5.3/10, moderate confidence.
Take-profit target: $51.11 (-8.1% upside). Prior stop was $44.00. Stop-loss: $44.00.
Target reached (-8.1% upside); Quality below floor (2.5 < 4.0); Value-trap signals (2/5): High leverage (D/E 3.0), Material insider selling (4 sells, 0.05% of cap).
Hemab Therapeutics Holdings, In trades at a P/E of N/A (forward -18.2). TrendMatrix value score: 4.0/10. Verdict: Sell.
11 analysts cover COAG with a consensus score of 4.3/5. Average price target: $50.
What does Hemab Therapeutics Holdings, In do?Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that...
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.